After Their U.S. Purchase, Algorithme Pharma Gains a Foothold in Europe Through the Acquisition of a New Clinical Research Location in the United Kingdom

Laval, Canada (ots/PRNewswire) - The Laval-based firm
Algorithme Pharma is pleased to announce that it has achieved its
goal of securing a European facility through its acquisition of
Simbec Research Ltd in Merthyr Tydfil, Wales. This news comes only
six weeks after confirming the purchase of another clinical research
centre in Baltimore, Maryland.

This important acquisition will enable Algorithme Pharma, a
worldwide leader in clinical research and bioanalysis, to continue
its international expansion plans, establish a foothold in Europe
for the very first time in its history and, most importantly, obtain
additional advanced scientific and medical expertise for its North
American teams.

"Given the considerable growth of our "international" clientele,
it became necessary to acquire a location in Europe in order to
better serve our fast-growing market once we had expanded to the
United States. The acquisition of this strategically-located and
highly-respected clinical research centre is the first step in our
European expansion strategy and provides us with an important base
for future growth in the European market," explains President and
Chief Executive Officer of Algorithme Pharma, Louis Caillé.

Simbec Research Ltd will continue its activities at its
headquarters as a new division of Algorithme Pharma. Simbec, along
with two other Phase I clinical research centres in the United
Kingdom, was recently given the official accreditation by the
Medecine Healthcare Regulatory Agency (MHRA), thereby joining a very
select group of companies that has earned the trust of governmental
regulatory authorities. The Simbec centre has specialized in Phase I
and IIa drug development clinical trials for some thirty years.

"The combination of Simbec Research and Algorithme Pharma offers
great promise, both for our employees and our clients and we are
delighted to be adding our Phase I expertise to Algorithme's
existing capacity. Having established a strong business in the area
of Clinical Research and Development we now look forward with
confidence to a future as part of the enlarged Algorithme Pharma
Group of companies", adds Brian Hallisey, Managing Director of
Simbec Research Ltd.

The new Phase I and IIa United Kingdom location for clinical
research includes a 38,000-square-foot facility with 48 beds (all
used by the Intensive Monitoring Unit), divided into five separate
research units, making it possible to carry out a number of studies
simultaneously. With this addition, Algorithme Pharma will increase
its production capacity in Phase I and IIa drug development clinical
trials. Simbec is a leader in clinical trials and bioanalysis and
has been providing contract clinical research services to large
pharmaceutical research and development companies for over 30 years.
The staff of the new Algorithme Pharma division in the United
Kingdom is composed of a core team of approximately 100 employees who
will join those already working at company locations in Montreal and
Laval, Canada and Baltimore, United States.

About Algorithme Pharma - As a worldwide leader in clinical
research and bioanalysis, Algorithme Pharma provides a wide range of
services for bioequivalence and early stage development (Phase
I/IIa) studies to the generic, pharmaceutical, and bio-technology
industries. In addition to its multi-unit clinical facilities in
Canada, the United States and the United Kingdom (more than 400
beds) and with its new dedicated state-of-the-art facility for Phase
I clinical trials in Montreal, Algorithme Pharma offers different
services including protocol designs, CTD/ICH clinical reports, data
management, biostatistics, quality assurance (QA) and regulatory
affairs.

Successfully audited by US FDA, Canada's TPD, Brazil's ANVISA,
France's AFSSAPS, UK's MHRA and more recently Austria's AGES
regulatory authorities, Algorithme Pharma conducts over 275 clinical
trials per year. Proud winner of Canada's 50 Best Managed Companies
since 2003, Algorithme Pharma's main success resides in the
flexibility and commitment of its 600 + dedicated and knowledgeable
employees to deliver first-class service to each client.

For further information: Media relations: Ingrid Saumart,
+1-514-490-0206, ingrids@sympatico.ca; Marius S. Brisson, President;
Source: Mr. Louis Caillé, President & Chief Executive Officer,
Algorithme Pharma; http://www.algopharm.com

ots Originaltext: Algorithme Pharma
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Media relations: Ingrid Saumart,
+1-514-490-0206, ingrids@sympatico.ca; Marius S. Brisson, President;
Source: Mr. Louis Caillé, President & Chief Executive Officer,
Algorithme Pharma